GEMCITABINE AND CISPLATIN ± VELIPARIB FOR PANCREAS ADENOCARCINOMA AND A GERMLINE BRCA/PALB2 MUTATION
A cohort of 50 patients with untreated locally advanced or metastatic pancreatic ductal adenocarcinoma and a germline mutation in BRCA1/2 or PALB2 was randomized to receive gemcitabine/cisplatin with or without veliparib in this multicenter phase II trial. The response rate was numerically but not statistically superior in the veliparib triplet group. The median progression-free and […]
